ARTICANZ - Beta (ver 0.9)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/KIT-inhibitor-first-generation

Search results

target/KIT-inhibitor-first-generation
9 trial(s) found.
NCT05678673
NCT05245968
NCT05208047
NCT03970447
ACTRN12624000532505
NCT05425940
NCT05328908
NCT05198934
NCT02773524
Filters
KIT
100%
PDGFR
100%
VEGFR
100%
FGFR
67%
FGFR1
67%
FGFR1/2/3
67%
FGFR2
67%
FGFR3
67%
FGFR4
67%
RET
67%
PD-1/PD-L1
33%
AXL
22%
MER
22%
MET
22%
PD-1
22%
VEGFR2
22%
BCR-ABL1
11%
HSP90
11%
PDGFRA
11%
PI3K-delta
11%
PI3K
11%
PI3Kalpha
11%
mTOR
11%
mTORC1
11%
mTORC2
11%
PD-L1
11%
LAG3
11%
EGFR
11%
HRAS G12C
11%
KRAS
11%
KRAS G12C
11%
NRAS G12C
11%




















 






























	
		
	

    

        

			ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

			
    
			
  • Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
    • 
			
			
  • Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
    • 
			
			
  • No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
    • 
			
			
  • External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.
    • 
			
			


			By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.
			
		

        

            
The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

            
            
Users are free to:

            
    
                
  • Share — copy and redistribute the data in any medium or format
    • 
                
  • Adapt — remix, transform, and build upon the data
    • 
                
  • Use the data for any purpose, including commercial use
    • 
            

            
            
Under the following terms:

            
    
                
  • Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
    • 
                
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
    • 
            

            
            
Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.